Long-term benefit of combining chemotherapy and radiotherapy in bladder cancer

Long-term benefit of combining chemotherapy and radiotherapy in bladder cancer
Image of a mouse bladder after surgery to remove a tumour. Credit: Frank C. Marini

Giving people with bladder cancer chemotherapy and radiotherapy at the same time helps stop cancer from coming back, long-term results of a 10-year study confirm.

Previous results showed that using the two treatments in combination to treat invasive , instead of radiotherapy alone, almost halves the risk of the cancer returning. This led to changes in clinical guidance, improving the quality of life for with bladder cancer.

The new findings from the phase III trial, led by researchers at The Institute of Cancer Research, London and the University of Birmingham, demonstrate that the benefit of combining chemotherapy and radiotherapy to reduce the risk of the disease returning is maintained over 10 years.

Sparing patients from invasive surgery

Treating invasive bladder cancer often involves surgery to remove the bladder—a process known as a cystectomy. However, patients are often too unwell to undergo surgery and it can lead to , usually resulting in patients wearing a drainage bag to collect urine.

Combining radiotherapy and chemotherapy is an , cutting the risk of recurrence and sparing patients from invasive surgery.

The 10-year follow-up study, involving the Clinical Trials and Statistics Unit at the ICR (ICR-CTSU), was funded by Cancer Research U.K. and published in the journal European Urology.

The trial recruited patients between 2001 and 2008. 178 people who were part of the trial received radiotherapy alone, while 182 were treated with both chemotherapy and radiotherapy. Clinicians followed these patients for an average of 10 years.

10 years after treatment

The research team looked at how many people were still living 10 years after . They found 30% who had chemoradiation were still alive, compared with 26% of those who had radiotherapy alone. There were 180 deaths due to bladder cancer in total—82 of the deaths were in the chemoradiation group and 98 in the radiotherapy group.

For this long-term follow-up analysis, researchers looked at whether cancer returned to the bladder or pelvic nodes. Outcomes were significantly better in the chemoradiation group: 63% of people treated with both chemotherapy and radiotherapy did not see their cancer return after five years, compared with 49% of people treated with radiotherapy alone.

Researchers also reported fewer "salvage cystectomies"—removal of the bladder after failed treatment—in the chemoradiotherapy group. After five years, 14% of people treated with chemoradiotherapy had to undergo a salvage cystectomy, compared with 22% of people treated with radiotherapy only.

Benefit is maintained in the long term

Study co-leader Professor Nick James, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, said: "Our findings are part of one of the largest ever of radiotherapy in bladder cancer. The latest data shows the benefit of adding chemotherapy to radiotherapy for is maintained in the long term. Overall, patients who received the combination are still doing better than those who only received radiotherapy, and we can conclude that combining both treatments helps stop bladder cancer from coming back. Adding chemotherapy to radiotherapy is therefore the best option for people who can't have, or want to avoid, an operation to remove their bladder."

'Already supported a change in clinical practice'

Professor Emma Hall, Deputy Director at the ICR Clinical Trials and Statistics Unit and methodology lead for the study, said: "Our initial results showed that adding chemotherapy to radiotherapy almost halves the risk of bladder cancer returning and can spare some patients from surgery. After longer follow-up, we can now confirm that this is still the case 10 years down the line.

"Findings from this trial have already supported a change in clinical practice. I hope patients will feel reassured to find out that, after so many years, the risk of recurrence after treatment with chemoradiation is still lower than with radiotherapy alone."

Lasting benefits for patients

Senior Specialist Cancer Information Nurse at Cancer Research U.K. Julia Frater said: "For people with cancer that has grown into the bladder muscle, combining and has benefited many over the years, so we are delighted to see these findings add to the evidence that underpins this treatment. Thanks to treatments like these, almost 1 in 2 people with cancer in England now survive their disease for 10 years or more.

"One of the quickest ways to make a difference to the lives of patients is to get the most out of the treatments we have, by combining different treatments or finding new and innovative ways to deliver those treatments. This study validates that approach, showing we can deliver lasting benefits for patients."

Explore further

Consumer health: Treating bladder cancer

More information: Emma Hall et al, Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial, European Urology (2022). DOI: 10.1016/j.eururo.2022.04.017
Journal information: European Urology

Citation: Long-term benefit of combining chemotherapy and radiotherapy in bladder cancer (2022, August 2) retrieved 7 October 2022 from https://medicalxpress.com/news/2022-08-long-term-benefit-combining-chemotherapy-radiotherapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors